A Recent Study from Yale Tracks the Progression of Scarring in Idiopathic Pulmonary Fibrosis
source: pixabay.com

A Recent Study from Yale Tracks the Progression of Scarring in Idiopathic Pulmonary Fibrosis

According to a story from EurekAlert!, a collaborative study headed by researchers from Yale University has furthered the understanding of the mechanisms and progression of fibrosis (scarring) in patients with…

Continue Reading A Recent Study from Yale Tracks the Progression of Scarring in Idiopathic Pulmonary Fibrosis
ICYMI: hATTR Amyloidosis was Untreatable Until a Gene Silencing Drug was Approved in the UK
source: pixabay.com

ICYMI: hATTR Amyloidosis was Untreatable Until a Gene Silencing Drug was Approved in the UK

  An article appeared recently in BioNews announcing the first-ever approval of an RNA-based therapy for use on the British National Health Service. The name of the drug is Patisiran…

Continue Reading ICYMI: hATTR Amyloidosis was Untreatable Until a Gene Silencing Drug was Approved in the UK
Life as a Parent of a Child With Glycogen Storage Disease: A Rare Disease Story From the Czech Republic
source: pixabay.com

Life as a Parent of a Child With Glycogen Storage Disease: A Rare Disease Story From the Czech Republic

When your child is constantly at risk of hypoglycemia and their health and life is threatened in the case of any major problem, you have no other choice but to…

Continue Reading Life as a Parent of a Child With Glycogen Storage Disease: A Rare Disease Story From the Czech Republic
An Experimental Treatment for Rett Syndrome Earns Rare Pediatric Disease Designation
source: pixabay.com

An Experimental Treatment for Rett Syndrome Earns Rare Pediatric Disease Designation

According to a story from marketscreener.com, the biopharmaceutical company Anavex Life Sciences Corp. has announced that its experimental product candidate ANAVEX2-73 has earned Rare Pediatric Disease designation from the US…

Continue Reading An Experimental Treatment for Rett Syndrome Earns Rare Pediatric Disease Designation

Breakthrough Therapy Designation Given to Investigative WHIM Syndrome Treatment

WHIM Syndrome WHIM syndrome is a form of primary immunodeficiency. It is caused by a mutation in the CXCR4 gene. WHIM stands for Warts, Hypogammaglobulinemia, Infections, and Myelokathexis. Throughout their…

Continue Reading Breakthrough Therapy Designation Given to Investigative WHIM Syndrome Treatment

PID Patients Could Receive More Personalized Treatment Thanks to New Study

A New Study A recent study published in Nature Immunology and conducted by researchers at the University of Basel has produced influential results regarding primary immunodeficiency disorders (PID). These rare disorders…

Continue Reading PID Patients Could Receive More Personalized Treatment Thanks to New Study